🚀 VC round data is live in beta, check it out!
PetMeds Valuation Multiples
Discover revenue and EBITDA valuation multiples for PetMeds and similar public comparables like Mister Spex, Talea Group, Claranova, Hamee and more.
PetMeds Overview
About PetMeds
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
Founded
1996
HQ
Employees
173
Website
Financials (FY)
EV
$24M
PetMeds Financials
PetMeds reported last fiscal year revenue of $232M and EBITDA of $7M.
In the same fiscal year, PetMeds generated $69M in gross profit, $7M in EBITDA, and had net loss of ($5M).
Revenue (LTM)
PetMeds P&L
In the most recent fiscal year, PetMeds reported revenue of $232M and EBITDA of $7M.
PetMeds expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $232M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $69M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 30% | XXX | XXX | XXX |
| EBITDA | — | XXX | $7M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 3% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 2% | XXX | XXX | XXX |
| Net Profit | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (2%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PetMeds Stock Performance
PetMeds has current market cap of $50M, and enterprise value of $24M.
Market Cap Evolution
PetMeds' stock price is $2.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $24M | $50M | 0.0% | XXX | XXX | XXX | $-0.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPetMeds Valuation Multiples
PetMeds trades at 0.1x EV/Revenue multiple, and 3.5x EV/EBITDA.
EV / Revenue (LTM)
PetMeds Financial Valuation Multiples
As of April 19, 2026, PetMeds has market cap of $50M and EV of $24M.
Equity research analysts estimate PetMeds' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PetMeds has a P/E ratio of (10.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50M | XXX | $50M | XXX | XXX | XXX |
| EV (current) | $24M | XXX | $24M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 6.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.3x | XXX | XXX | XXX |
| P/E | — | XXX | (10.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (59.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PetMeds Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PetMeds Margins & Growth Rates
PetMeds' revenue in the last fiscal year declined by (6%).
PetMeds' revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.4M for the same period.
PetMeds Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (6%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PetMeds Public Comps
See public comps and valuation multiples for other Consumer E-commerce and Pet Care comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PetMeds | XXX | XXX | XXX | XXX | XXX | XXX |
| Mister Spex | XXX | XXX | XXX | XXX | XXX | XXX |
| Talea Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Claranova | XXX | XXX | XXX | XXX | XXX | XXX |
| Hamee | XXX | XXX | XXX | XXX | XXX | XXX |
| Delticom | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PetMeds M&A Activity
PetMeds acquired XXX companies to date.
Last acquisition by PetMeds was on XXXXXXXX, XXXXX. PetMeds acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PetMeds
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPetMeds Investment Activity
PetMeds invested in XXX companies to date.
PetMeds made its latest investment on XXXXXXXX, XXXXX. PetMeds invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PetMeds
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PetMeds
| When was PetMeds founded? | PetMeds was founded in 1996. |
| Where is PetMeds headquartered? | PetMeds is headquartered in United States. |
| How many employees does PetMeds have? | As of today, PetMeds has over 173 employees. |
| Who is the CEO of PetMeds? | PetMeds' CEO is Leslie C.G. Campbell. |
| Is PetMeds publicly listed? | Yes, PetMeds is a public company listed on Nasdaq. |
| What is the stock symbol of PetMeds? | PetMeds trades under PETS ticker. |
| When did PetMeds go public? | PetMeds went public in 1997. |
| Who are competitors of PetMeds? | PetMeds main competitors are Mister Spex, Talea Group, Claranova, Hamee. |
| What is the current market cap of PetMeds? | PetMeds' current market cap is $50M. |
| What is the current revenue of PetMeds? | PetMeds' last fiscal year revenue is $232M. |
| What is the current EV/Revenue multiple of PetMeds? | Current revenue multiple of PetMeds is 0.1x. |
| Is PetMeds profitable? | No, PetMeds is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.